Joel Isaacson & Co’s Myriad Genetics MYGN Stock Holding History

Joel Isaacson & Co’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2,000	Closed	-$33K	–	397
2016 Q4	$33K	Hold	2,000	–	–	0.01%	367
2016 Q3	$41K	Hold	2,000	–	–	0.01%	359
2016 Q2	$61K	Hold	2,000	–	–	0.01%	300
2016 Q1	$75K	Hold	2,000	–	–	0.02%	280
2015 Q4	$86K	Hold	2,000	–	–	0.02%	249
2015 Q3	$75K	Hold	2,000	–	–	0.02%	266
2015 Q2	$68K	Hold	2,000	–	–	0.02%	316
2015 Q1	$71K	Buy	+2,000	New	+$71.6K	0.02%	310

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Joel Isaacson & Co's MYGN Position: Q1 2017 in Review

Joel Isaacson & Co sold out of Myriad Genetics (MYGN) in Q1 2017, closing a stake of 2,000 shares — an estimated $33K sold.

Joel Isaacson & Co first reported a position in MYGN in Q1 2015 and held it in 8 quarters. The position peaked at $86K in Q4 2015. 233 funds tracked by Wall St. Rank hold MYGN as of Q1 2017.

Joel Isaacson & Co reported no remaining Myriad Genetics position as of Q1 2017 after selling out during the quarter.
Joel Isaacson & Co sold 2,000 Myriad Genetics shares in Q1 2017, an estimated $33K.
Joel Isaacson & Co first reported a position in Myriad Genetics in Q1 2015 and held it in 8 quarters.
Joel Isaacson & Co's Myriad Genetics position peaked at $86K in Q4 2015.
233 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2017.

Based on Joel Isaacson & Co's 13F filing for Q1 2017, filed 5 May 2017.